BRAF and melanoma: Unlike simple biomarkers such as BRAF p.V600E mutation detection for predicting BRAF/MEK inhibition in melanoma and other tumor types, TMB has numerous potential challenges as a predictive biomarker, including the potential for tumor-only CGP to overestimate TMB (and TMB-H rates) due to the inappropriate inclusion of true germline variants as false-positive somatic mutations.